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 Pseudoexfoliation syndrome (PES) is characterized by
deposits of grayish-white material throughout the anterior seg-
ment that are generally most easily recognizable around the
pupillary border and over the lens surface. PES is frequently
associated with pseudoexfolation glaucoma (PEG), which of-
ten has a more serious clinical course and worse prognosis
than the more common primary open angle glaucoma (POAG).
Cataract and central retinal vein occlusion occur more often,
and cataract surgery is sometimes complicated by fragile
zonules and lens capsule as well as poor pupillary dilation.
PES may be a systemic condition [1,2] associated with sys-
temic hypertension, transient ischemic attacks, stroke, and
myocardial infarction [3,4], and recent studies have strength-
ened claims that inheritance plays a potential role [5,6]. In
fact, nearly all reported PES pedigrees suggest maternal trans-
mission, raising the possibility of mitochondrial inheritance
[7,8]. Matrilineal inheritance, variable expression, late age of
onset, multisystem involvement, and reduced amount of mi-
tochondria in iris tissue are all features consistent with mito-
chondrial involvement [5,7,8].
In a previous study of adult onset POAG, we reported an
increased frequency of nonsynonymous (NS) mitochondrial
DNA (mtDNA) sequence changes and decreased mitochon-
drial respiration in patients compared to controls [9]. These
results raise the question of whether abnormal mitochondria
play a role in other types of glaucoma as well. The aim of the
current study was a similar evaluation of PEG patients for the
presence of mitochondrial abnormalities and nuclear gene
mutations associated with various types of glaucoma (MYOC,
OPTN, WDR36, and CYP1B1) and certain inherited optic neu-
ropathies (OPA1 and OPA3) [10-12].
METHODS
Patient enrollment:  Patients were eligible for inclusion in this
study if they had in at least one eye: (1) characteristic
pseudoexfoliation grayish-white particles over the pupillary
border and/or surface of the lens noticed before or after pupil-
lary dilation; (2) glaucomatous optic disc changes diagnosed
by vertical excavation measuring at least 0.65 cup-to-disc (c/
d) ratio with localized thinning of the rim in one or both verti-
cal poles; and (3) glaucomatous visual field loss including
nerve fiber bundle defects (nasal step, arcuate scotoma, para-
central scotoma) or advanced visual field loss (central and/or
temporal island of vision). Exclusion criteria included a his-
tory of other possible optic neuropathies affecting either eye,
significant visual loss in both eyes not associated with glau-
coma, lack of adequate visualization of the fundus for disc
assessment, or refusal to participate.
Patients were selected from the Glaucoma Clinic at King
Khaled Eye Specialist Hospital after examination by a glau-
coma specialist (J.M.) and after signing informed consent ap-
proved by the KKESH-IRB. Records were reviewed, and full
ophthalmologic examinations were performed. Patients had
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29either Goldmann manual kinetic perimetry (Haag Streit Inter-
national, Koeniz-Bern) or Humphrey automated white on white
stimulus static perimetry (Humphrey Field Analyzer II,
Humphrey Systems, Dublin, California), or both. Optical Co-
herence Tomography was performed with the OCT3 Unit by
Humphrey Systems (San Leandro, CA) on some patients. Fun-
dus photos were obtained using a Zeiss FF 450 system and
conventional film. This research followed the tenets of the
Declaration of Helsinki. Family members were not evaluated
clinically or genetically.
Control enrollment:  Control subjects were blood donors
at the King Faisal Specialist Hospital and Research Centre
who represented the spectrum of Saudi Arabs and who re-
ported no symptomatic metabolic, genetic, or ocular disor-
ders on an extensive questionnaire about family history, past
medical problems, and current health. Health information was
obtained from controls only through the questionnaire; none
had a physical or ophthalmological examination. The control
group for mitochondrial DNA (mtDNA) sequencing consisted
of 159 individuals (106 males and 53 females, mean age
46.3±3.8 years); for relative mtDNA content, 28 different in-
dividuals (19 males and 9 females, mean age of 59.2±3.3
years); and for mitochondrial respiration testing, 50 different
individuals (39 males and 11 females, mean age 59.0±6.7
years). Information of family history was obtained from par-
ticipating members. All patients and control subjects were of
Middle Eastern Arabic origin.
Sample collection and DNA extraction:  Ten ml of pe-
ripheral blood were collected in EDTA tubes from all partici-
pating individuals after obtaining their written consent. DNA
was extracted from whole blood samples of all PEG patients
and controls using the PUREGENE DNA isolation kit from
Gentra Systems (Minneapolis, MN).
Isolation of lymphocytes from peripheral blood and prepa-
ration of cell suspension:  Blood (5 ml) was diluted with phos-
phate buffered saline (PBS) at a ratio of 1:1 within 1 h of
extraction and slowly layered onto a 15 ml screw cap tube
containing 4.5 ml Ficoll-Hypaque separating solution. The
tubes were centrifuged for 20 min at 1,000 xg after which the
lymphocyte-containing layer was collected into a new centri-
fuge tube using a sterile pipette. The lymphocytes mix was
then diluted in 10 ml PBS and centrifuged for 10 min at 660
xg. The supernatant was discarded, 5 ml of hypotonic PBS
lysing buffer was added, the pellet was mixed gently in this
buffer, and the mixture was allowed to sit for about 45 s. Five
ml of 2X NaCl solution was added. The mixture was gently
pipetted and then centrifuged at 600 xg for 10 min. The super-
natant was discarded, and the pellet was suspended in RPMI-
1640 medium (Gibco, Invitrogen Corporation, Carlsbad, CA)
supplemented with L-glutamine. The optical density (OD 660)
of the lymphocyte suspension was adjusted to 0.20, which is
equivalent to a cell density of approximately 5x105 cells/ml.
Using this protocol, cell viability assessed by 0.2% trypan blue
was 96±2%. These cells were used for mitochondrial respira-
tion testing.
Sequence analysis of nuclear genes:  The coding exons,
exon-intron boundaries, and promoter regions in the MYOC,
OPTN, CYP1B1, and WDR36 genes were amplified by PCR
from genomic DNA for all patients and controls and subjected
to direct sequencing as described previously [13]. The 31 cod-
ing exons, exon-intron boundaries, and promoter regions of
the OPA1 gene were amplified by PCR from genomic DNA
for all patients and subjected to direct sequencing as described
previously [14]. Similarly, the entire OPA3 gene was sequenced
in all patients using the protocol described previously [12].
DNA amplification and sequencing:  The entire coding
region of the mitochondrial genome was amplified in all pa-
tients and controls in 24 separate polymerase chain reactions
(PCRs) using single set cycling conditions as detailed else-
where [15]. Primers were used to amplify the entire coding
region of the mitochondrial genome except the D-loop [16].
PCRs were run under the following PCR conditions: 20 ng of
each DNA sample in a 50 ml PCR reaction mixture contain-
ing 200 mM dNTP, 0.2 mM of each primer-pair, 1 unit of
TaqDNA polymerase, 50 mM KCL, 1.5 mM MgCl2 and 10
mM Tris-HCl (pH 8.3). Polymerase chain reaction was per-
formed for 35 cycles and 55 °C annealing temperature in a
GeneAmp 9700 PCR (Perkin-Elmer, Foster City, CA). PCR-
Primers were designed to avoid amplifying mtDNA-like se-
quences in the nuclear genome. Each successfully amplified
fragment was directly sequenced using the same primers used
for amplifications and the BigDye Terminator V3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA).
Samples were run on the ABI prism 3100 sequencer (Applied
Biosystems). A similar sequencing protocol was followed for
the nuclear genes.
Sequence analysis of the mitochondrial DNA coding re-
gion:  The full mtDNA genome was sequenced except for the
D-loop. Sequencing results were compared to the corrected
Cambridge reference sequence [16]. All fragments were se-
quenced in both forward and reverse directions at least twice
for confirmation of any detected variant. All sequence vari-
ants from both PEG patients and controls were compared to
the Human Mitochondrial Genome Database (Mitomap) [17],
GenBank, and Medline listed publications. Reported synony-
mous or NS polymorphisms used mainly for haplogroup analy-
sis were excluded from further consideration [18].
Prediction of pathogenicity:  Pathologic characteristics
of each remaining nucleotide change in both PEG patients and
controls were assessed according to a combination of: stan-
dard criteria [19]; an evaluation of interspecies conservation
using the PolyPhen database, and the Mamit-tRNA website
when a sequence variant is detected in the tRNA region; as-
sessment of the possible impact of an amino acid substitution
on three-dimensional protein structure using the Protean pro-
gram, part of the LASERGENE V.6 software (DNASTAR,
Inc. Madison, WI), which predicts and displays secondary
structural characteristics; and assessment of the possible ef-
fect of the mtDNA change on protein function using PolyPhen
[20]. Therefore, a NS sequence change was considered patho-
logic if it met all of the following criteria, when applicable:
(1) it was not a haplogroup-determining polymorphism; (2) it
was not reported in mitochondrial databases or available lit-
erature as an established polymorphism; (3) it was not found
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TABLE 1. CLINICAL CHARACTERISTICS OF PEG PATIENTS
                       PXF    IOP   IOP
Patient   Age   Sex   side    OD    OS     c/d OD    c/d OS    VA OD    VA OS         VF OD           VF OS
-------   ---   ---   -----   ---   ---   --------   -------   ------   ------   ---------------   -----------
1          77    M    Both    24    25    0.75/.7    0.85/.8   20/30    20/20    Inferior          Inferior
                                                                                 arcuate scotoma   arcuate
                                                                                 with nasal step   scotoma
                                                                                                   with nasal
                                                                                                   step
2          65    M    Both    42    46    0.8 /.8    0.9 /.9   20/30    20/25    Central island    Central
                                                                                 remnant           island
                                                                                                   remnant
3          69    M    Both    35    44    0.75/.7    0.95/.9   20/20    20/400   Central island    Inferior
                                                                                 remnant           arcuate
                                                                                                   scotoma
                                                                                                   with nasal
                                                                                                   step and
                                                                                                   split
                                                                                                   fixation
4          73    M    Right   26    25    0.95/.9    0.8 /.8    1/200   20/40    Superior          Central
                                                                                 arcuate scotoma   scotoma
                                                                                 + nasal step
5          71    F    Both    27    22    0.9 /.85   0.5 /.5   20/100   20/50    Inferior          Inferior
                                                                                 arcuate scotoma   nasal step
                                                                                 with nasal step
6         100    M    Both    19    19    0.9 /.8    0.95/.9   20/60     HM      Generalized       Unable
                                                                                 non-specific
                                                                                 depression
7          79    F    Both    36    40    0.95/.9    0.9 /.8   20/50    20/40    Central island    Central
                                                                                 remnant           island
                                                                                                   remnant
8          63    F    Left    19    34    0.4 /.4    0.95/.9   20/30     4/200   Normal            Central
                                                                                                   island
                                                                                                   remnant
9          69    M    Both    20    27    0.4 /.4    0.7 /.6   20/20    20/30    Normal            Superior
                                                                                                   and
                                                                                                   inferior
                                                                                                   arcuate
                                                                                                   scotomas
                                                                                                   with nasal
                                                                                                   step
10         67    M     Both    30    28   0.9 /.8    0.6 /.5   20/20    20/25    Central island    Small nasal
                                                                                 remnant           step
11         71    F     Left    20    30   0.95/.9    0.6 /.5   20/100   20/40    Central island    Generalized
                                                                                                   depression
12         69    M     Both    20    17   0.95/.9    0.8 /.8   20/100   20/30    Central island    Non
                                                                                 remnant           specific
                                                                                                   diffuse
                                                                                                   depression
13         62    F     Right   40    20   0.95/.9    0.3 /.2    HM      20/40    Temporal island   Normal
                                                                                 remnant
14         65    M     Both    44    38    Pros.     0.95/.9    NLP      HM      Unable            Central and
                                                                                                   temporal
                                                                                                   island
15         49    M     Right   34    30   0.75/.7    0.95/.9   20/30    20/125   Inferior          Dense
                                                                                 arcuate scotoma   superior
                                                                                 with nasal step   and
                                                                                                   inferior
                                                                                                   arcuate
                                                                                                   scotomas
                                                                                                   approaching
                                                                                                   fixation
16         65    M     Both    28    30   0.8 /.5    0.5 /.5   20/25    20/20    Inferior          Inferior
                                                                                 arcuate scotoma   nasal step
                                                                                 and inferior
                                                                                 nasal step
17         60    M     Left    21    46   0.75/.7    0.95/.9   20/25     NLP     Inferior          Unable
                                                                                 arcuate scotoma
                                                                                 and inferior
                                                                                 nasal step
18         72    M     Left    39    40   0.85/.8    0.99/.9   20/50     NLP     Inferior          Unable
                                                                                 arcuate scotoma
                                                                                 with nasal step
31in at least 100 controls of matching ethnicity; (4) it changed a
moderately or highly conserved amino acid; (5) Protean pre-
dicted an alteration of protein structure; and (6) it was assessed
as possibly or probably pathologic by PolyPhen. For previ-
ously reported NS nucleotide changes, consideration was given
to pathologic status determined by others and by mitochon-
drial databases in addition to these criteria.
Determination of relative mitochondrial DNA content:  A
competitive multiplex PCR was performed with two simulta-
neous primer sets as described previously [21]. This technique
has been applied successfully to a variety of tissues [22,23],
including blood of patients with LHON [24] and other spon-
taneous optic neuropathies [9,25,26]. One primer-pair was
designed to amplify a 450 bp fragment of the ND1 mitochon-
drial gene (forward primer sequence 5'-ACA TAC CCA TGG
CCA ACC TC-3' and reverse primer sequence 5'-AAT GAT
GGC TAG GGT GAC TT-3'), while a second primer-pair was
used in the amplification of a 315 bp fragment of the β-actin
nuclear gene (forward primer sequence 5'-ATG TTT GAG
ACC TTC AAC AC-3' and reverse primer sequence 5'-CAT
CTC TTG CAC GAA GTC GA-3'), which served as an inter-
nal control. Control and patient PCRs were run simultaneously
under the following PCR conditions: 20 ng of each DNA
sample in a 50 ml PCR reaction mixture containing 200 mM
dNTP, 0.2 mM of each of the ND1 primer-pair, 0.6 mM of
each of the β-actin primer-pair, 1 unit of Taq DNA polymerase,
50 mM KCL, 1.5 mM MgCl2 and 10 mM Tris-HCl (pH 8.3).
Polymerase chain reaction was performed for 25 cycles in a
GeneAmp 9700 PCR system (Perkin-Elmer). One ml of
SYBR® Green I stain was added to the reaction mixture in
the last cycle to label the PCR products. PCR products were
separated on 1% agarose gel at 100 V for 1 h, and intensity of
the two bands was quantified by the use of gel imager (Ty-
phoon 9410; GE Amersham Biosciences, Schenectady, NY).
The ratio of ND1 to β-actin was determined for each patient
and control by dividing the fluorescence intensity of the ND1
band by the intensity of the β-actin band.
Measurement of mitochondrial respiration:  Resazurin is
a redox-active blue dye that fluoresces and turns pink when
reduced. It competes with oxygen for electrons in a standard
preparation of circulating lymphocytes, and the resulting
change in fluorescence (corrected for background and protein
concentration) reflects respiration. Lymphocytes from patients
and controls were incubated with 6 µM resazurin without and
with mitochondrial inhibition by amiodarone 200 µM, and the
fluorescence intensity resulting from resazurin reduction was
monitored spectrofluorimetrically over time. Mitochondrial
respiratory activity (MRA) was calculated as the difference
between uninhibited and inhibited measurements at 240 min.
Measurements taken in triplicate were averaged and normal-
ized for protein concentration and background activity as de-
scribed previously [27]. Mitochondrial metabolic activity has
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TABLE 1, CONTINUED.
19         60    M     Both    35    17   0.65/.6    0.3 /.2   20/60    20/30    Superior and      Normal
                                                                                 inferior
                                                                                 arcuate
                                                                                 scotomas
20         69    M     Both    20    43   0.5 /.5    0.95/.9   20/40     HM      Small inferior    Unable
                                                                                 nasal step
21         65    M     Right   42    24   0.9 /.8    0.85/.8   20/100   20/50    Central island    Superior
                                                                                 remnant           hemifield
                                                                                                   defect with
                                                                                                   inferior
                                                                                                   paracentral
                                                                                                   scotoma
22         84    M     Right   21    60   0.9 /.8    unable    20/300    NLP     Superior          Unable
                                                                                 arcuate scotoma
                                                                                 with nasal step
23         57    M     Right   31    22   0.9 /.8    0.4 /.4   20/25    20/20    Central island    Normal
                                                                                 remnant
24         68    M     Right   35    53   0.6 /.5    0.95/.9   20/100    HM      Generalized       Unable
                                                                                 depression
25         76    M     Left    43    54   0.6 /.5    0.95/.9   20/20    20/200   Early inferior    Central
                                                                                 nasal step        island
                                                                                                   remnant
26         51    M     Left    18    40   0.4 /.4    0.85/.8   20/25    20/20    Normal            Central
                                                                                                   island
                                                                                                   remnant
27         67    M     Both    50    22   0.95/.9    0.7 /.6    LP      20/30    Unable            Central
                                                                                                   island
                                                                                                   remnant
28         81    M     Left    17    33   0.85/.8    0.95/.9   20/60     HM      Central island    Unable
                                                                                 remnant
29         65    M     Both    22    50   0.95/.9    0.99/.9   20/80     NLP     Central island    Unable
                                                                                 remnan
Age=age in years; IOP=maximum documented intraocular pressure; OD=right eye; OS=left eye; c/d=cup to disk ratio in vertical/horizontal
dimensions; VA=visual acuity by Snellen plates; VF=results of Goldmann and/or Humphrey visual field; M=male; F=female; HM=hand
motion; LP=light perception; NLP=no light perception
32been assessed using Resazurin in synaptosomes from spinal
cord-injured animals [28], neonatal rat cerebellum [29], and
in isolated yeast mitochondria [30]. The current technique has
been validated in systemic mitochondrial disorders [27] in-
cluding LHON-like optic neuropathies [25].
Statistical methods:  All statistical analyses were per-
formed using SPSS for Windows version 15.0 (SPSS Inc.,
Chicago, IL). Snellen visual acuities were converted to ordi-
nal values. Statistical comparisons included bivariate correla-
tion, independent samples t-test, and Fisher’s Exact Analysis.
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TABLE 2. NONSYNONYMOUS MTDNA SEQUENCE CHANGES DETECTED IN PEG PATIENTS
                                         Base
 Nucleotide      AA                  substitution   Controls           Interspecies
substitution   change    Location        type         (%)      Novel   conservation   Protean   PolyPhen      Summary
------------   ------   ----------   ------------   --------   -----   ------------   -------   --------   --------------
3833 T>A       L176Q    TM domain    Transversion     0         Yes      Moderate       Yes     Probably   Pathologic
                        of ND1                                                                  damaging
                        gene
4363 T>C       N/A      Anticodon    Transition       0.62       No        High         N/A     Unknown    Non-pathologic
                        loop of
                        tRNA
                        glutamine
4385 A>G       N/A      In the T?C   Transition       0.62       No        High         N/A     Unknown    Non-Pathologic
                        domain of
                        the tRNA
                        glutamine
4648 T>C       F60S     Outside      Transition       0         Yes        High         Yes     Probably   Pathologic
                        the TM                                                                  damaging
                        domain of
                        ND2 gene
5182 C>T       T238M    Outside      Transition       0         Yes        Low          No      Benign     Non-Pathologic
                        the TM
                        domain of
                        ND2 gene
5843 A>G       N/A      In the       Transition       1.2        No        High         N/A     Unknown    Non-pathologic
                        D-loop of
                        tRNA
                        tyrosine
6546 C>T       L215F    Outside      Transition       0.62       No        High         No      Benign     Non-pathologic
                        the TM
                        domain of
                        COI gene
7877 A>C       K98Q     Outside      Transversion     0         Yes        High         No      Probably   Pathologic
                        the TM                                                                  damaging
                        domain of
                        COII gene
9103 T>C       F193L    Outside      Transition       1.2        No      Moderate       No      Benign     Non-pathologic
                        the TM
                        domain of
                        ATPase 6
                        gene
9438 G>A       G78S     Outside      Transition       3.14       No        High         No      Benign     Non-pathologic
                        the TM
                        domain of
                        COIII gene
11337 A>G      N193S    TM domain    Transition       1.9        No        Low          No      Benign     Non-pathologic
                        of ND4
                        gene
12841 A>G      I169V    Outside      Transition       3.1        No        Low          No      Benign     Non-pathologic
                        the TM
                        domain of
                        ND5 gene
13813 G>A      V493I    TM domain    Transition       1.9        No        High         No      Benign     Non-pathologic
                        of ND5
                        gene
In the “Base substitution type” column, Transversion=A mutation in which a purine/pyrimidine replaces a pyrimidine/purine base pair or vice
versa (G:C>T:A or C:G, or A:T>T:A or C:G); Transition=A mutation in which a purine/pyrimidine base pair is replaced with a base pair in the
same purine/pyrimidine relationship (A:T>G:C or C:G>T:A). Controls (%)=percent of controls with this nucleotide substitution. Previous
reports of sequence variants were found in the Human Mitochondrial Genome Database (MITOMAP database), GenBank, and Medline listed
publications. Interspecies conservation was assessed using the Polymorphism Phenotyping (PolyPhen) database, which determines interspecies
conservation for an altered amino acid by performing alignment with all available amino acid sequences for other species, and the Mamit-
tRNA website when necessary. Protean predicts and displays secondary structural characteristics. “Yes”=nucleotide change will alter protein
secondary structure; “No”=change will not alter secondary structure. PolyPhen prediction of pathogenicity was assessed using the PolyPhen
database. “Probably damaging” constitutes a high confidence of affecting protein function or structure. “Possibly damaging” reflects a likeli-
hood of affecting protein function or structure, while “Benign” changes most likely lack phenotypic effect. “Unknown” means that PolyPhen
could not make a prediction due to lack of data. None of these nucleotide changes was heteroplasmic. Summary; see Prediction of Pathogenic-
ity in Methods. TM= transmembrane. N/A=not applicable because the database is not designed to predict this type of sequence change.
Reported haplogroup specific NS sequence changes were excluded from Table 2 and further analysis.
33RESULTS
Clinical information:  Table 1 details the clinical characteris-
tics of 29 unrelated PEG patients (mean age 68.58 ±9.95 SD
years; 24 males and five females) who met inclusion and ex-
clusion criteria. Fifteen patients had bilateral and 14 had uni-
lateral pseudoexfoliation material. Seventeen patients had open
anterior chamber angles and 12 patients had undergone laser
iridotomies to treat a narrow angle component. Fifteen pa-
tients had a visual acuity of 20/200 or less in at least one eye.
Results of Optical Coherence Tomography testing and fundus
photos were consistent with the clinical assessment of optic
disc damage (data not shown).
Sequence analysis of MYOC, OPTN, WDR36, CYP1B1,
OPA1, and OPA3: No novel or previously reported sequence
mutation was found in MYOC, OPTN, WDR36, CYP1B1,
OPA1, or OPA3 genes in PEG patients or controls. Patients
had no previously reported or novel polymorphisms in any of
these genes, and controls had only polymorphisms reported
previously [9].
Sequence analysis of the mitochondrial coding region:
The prevalence of NS mtDNA nucleotide changes in PEG
patients was not different from controls (Fisher’s Exact Analy-
sis p=0.86). Table 2 details the 13 NS mtDNA changes found
in PEG patients after excluding all synonymous mtDNA
changes, established NS polymorphisms, and NS mtDNA se-
quence changes relevant primarily to haplogroup designation.
Four of these mtDNA sequence changes were novel (not pre-
viously reported), and the remaining nine were also found in
ethnicity-matched controls. All previously reported nucleotide
changes were transitions, while two of the novel changes were
transversions and two transitions. None were heteroplasmic.
Three novel NS mtDNA sequence changes were considered
pathologic using the criteria described in the Methods.
Two of these mtDNA sequence alterations (nt 3833 and
nt 4648) cause amino acid (AA) changes (L176Q in ND1 and
F60S in ND2, respectively) in Complex I (NADH: ubiquinone
oxidoreductase), which is a major component of the oxidative
phosphorylation machinery responsible for producing much
of the ATP required by cells. The third potentially pathologi-
cal mtDNA nucleotide change (nt 7877) causes an AA change
(K98Q) in the COII gene of Complex II (succinate: ubiquinone
oxidoreductase), which performs a key step in the citric acid
cycle in which succinate is dehydrogenated to fumarate and
electrons are donated to ubiquinone in the mitochondrial in-
ner membrane. Mutations in either Complex I or Complex II
may impair the electron transfer process and result in decreased
ATP production and/or accumulation of reactive oxygen spe-
cies, although this cannot be proven without investigating
mitochondrial cybrids. The nt 3833 nucleotide change replaces
the AA Leucine (hydrophobic) with Glutamine (neutral),
changing the hydrophilicity index and possibly altering pro-
tein structure flexibility. The nt 4648 nucleotide change re-
places Phenylalanine (hydrophobic) with Serine (neutral),
changing the hydrophilicity index and possibly causing a loss
of Alpha region with introduction of an aberrant Beta region
at that AA location. The nt 7877 nucleotide change replaces
Lysine (hydrophilic) with Glutamine (neutral), altering the
hydrophilicity index and changing protein flexibility.
Table 3 details mtDNA sequence changes in each patient.
Seventeen patients (Patients 1-17) had no NS mtDNA sequence
changes listed in Table 2, while nine (Patients 18-26) had NS
sequence changes predicted to be non-pathologic. The three
potentially pathologic mtDNA sequence changes were present
in three different patients (Patients 27-29).
Relative mitochondrial DNA content and mitochondrial
functional testing:  Table 3 also details relative mtDNA con-
tent and MRA by patient. Mean relative mtDNA content in
PEG patients (1.18 ±0.25; 95% CI 1.09-1.28) was not signifi-
cantly different from controls (1.18 ±0.17; 95% CI 1.12-1.25;
p=0.98). Likewise, MRA in PEG patients (20.97 ±1.03; 95%
CI 20.58-21.36) was not significantly different from controls
(21.25 ±0.80; 95% CI 21.03-21.25; p=0.177).
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TABLE 3. MTDNA AND MITOCHONDRIAL RESPIRATORY CHANGES IN
PEG PATIENTS
                        Relative
          Nucleotide     mtDNA
Patient   change (s)    content    MRA
-------   -----------   --------   ----
1         None            1.20     21.6
2         None            1.35     21.8
3         None            1.20     21.9
4         None            1.90     19.6
5         None            1.40     20.4
6         None            1.30     21.6
7         None            1.20     21.6
8         None            1.10     22.5
9         None            1.20     20.5
10        None            1.10     19.8
11        None            1.30     18.9
12        None            1.50     21.9
13        None            1.30     21.4
14        None            0.92     21.9
15        None            0.81     22.5
16        None            1.10     21.4
17        None            1.08     19.8
18        5182            0.80     21.4
19        4363            1.20     20.4
20        4385, 12841     1.20     21.5
21        9438            1.60     20.8
22        5843            1.20     20.2
23        9103, 13813     0.83     21.9
24        9103            0.82     21.8
25        11337           1.20     20.4
26        4385, 6546      1.09     18.6
27        3833            0.85     19.8
28        7877            1.20     20.8
29        4648            1.40     21.4
PEG patients organized according to characteristics of “Nucleotide
Change(s)” from Table 2 for each patient. Patients 1-17 had no note-
worthy mtDNA changes (see Methods), while patients 18-26 had NS
mtDNA changes not thought to be pathologic, and patients 27-29
had NS mtDNA changes thought likely to be pathologic (see Meth-
ods). Relative mtDNA Content=ratio of ND1 to β-actin (see Meth-
ods). MRA=Mitochondrial Respiratory Activity (see Methods).
34DISCUSSION
 We evaluated 29 patients who had pseudoexfoliation mate-
rial in the anterior chamber and met anterior segment, fundo-
scopic and visual field criteria that define PEG. None of the
patients met criteria for POAG or PACG, and none had the
clinical characteristics of other spontaneous optic neuropa-
thies associated with mitochondrial abnormalities such as
Leber hereditary optic neuropathy [31]. As a group, they had
relatively advanced ophthalmologic disease with 15 being le-
gally blind in one eye, 2/3 having severe central or peripheral
visual field loss, and almost half requiring a glaucoma surgi-
cal procedure. Compared to a group of POAG patients evalu-
ated previously in a similar fashion [9], these PEG patients
had slightly worse VA and slightly more surgical interven-
tions.
No patient had a novel or previously described mutation
in one of the nuclear genes investigated here. MYOC, OPTN,
WDR36, and CYP1B1 have all been identified in a relatively
small percentage of patients with various types of glaucoma,
and it remains possible that these genes are abnormal with a
small percentage of PEG patients. This is the first time that
these genes, or OPA1 and OPA3, have been completely se-
quenced in patients with PEG, but a report of a recent ge-
nome-wide screen of Icelandic and Swedish populations [32]
also failed to identify an association between PEG and the
nuclear genes evaluated here. The study did detect an associa-
tion of PEG with two nonsynonymous SNPs in exon 1 of the
LOXL1 gene. PES has a familial association [7,8] and may
have a nuclear genetic predisposition due to mutation of the
LOXL1 gene or to other nuclear genes not yet identified.
Mitochondrial function is multifaceted, and various mi-
tochondrial abnormalities have variable, and currently unpre-
dictable, effects on different tissues. This study evaluated three
mitochondrial parameters (the entire mitochondrial DNA cod-
ing region sequence, relative mtDNA content, and mitochon-
drial respiratory activity) that address mitochondrial structure
and function from three largely unrelated perspectives. This
evaluation is not comprehensive, but these mitochondrial pa-
rameters taken together have the potential of detecting dispar-
ate mitochondrial abnormalities. Abnormalities in these three
mitochondrial parameters have proven to be aligned in cer-
tain (e.g., LHON-like optic neuropathies [25]), but not all (e.g.,
POAG [9]), spontaneous optic neuropathies. In the PEG pa-
tients reported here, only three patients (10.3%) had mtDNA
sequence changes that were predicted to be pathologic, a
smaller representation of mtDNA abnormalities than found in
several other spontaneous optic neuropathies [9,25,33,34].
Neither relative mtDNA content nor MRA was changed in
PEG patients compared to matching controls. These results
imply that the nuclear and mitochondrial factors investigated
here are likely less important than anatomic and dynamic dis-
turbances consequent to deposition of pseudoexfoliation ma-
terial in the anterior chamber.
These largely negative results in PEG patients are similar
to data documented in patients with PACG [35]. Although PEG
and PACG have different mechanisms, the intermediate result
is elevation of IOP which, in turn, is a likely primary cause of
optic nerve injury. This mechanism contrasts with the molecu-
lar and biochemical abnormalities suspected in POAG [36],
just as the PEG results reported here contrast dramatically with
the substantial mitochondrial abnormalities observed in a group
of POAG patients [9], highlighting the potential importance
of mitochondrial malfunction as a metabolic risk factor for
POAG. We report a relatively small number of Middle East-
ern Arabian patients, and these genetic and mitochondrial stud-
ies should be confirmed in other ethnicities and extended to
other types of glaucoma.
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